AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

By Yadarisa Shabong (Reuters) -AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The deal is AstraZeneca (NASDAQ:AZN)\'s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up...

Read More

Guggenheim Neutral on TaskUs stock, sets $13 target on growth strategy balance

On Tuesday, Guggenheim initiated coverage on TaskUs, Inc stock(NASDAQ:TASK) with a Neutral rating and a price target set at $13.00. The firm\'s analysis suggests that while TaskUs is positioned to return to year-over-year revenue growth, the current risk and reward dynamics are evenly balanced. The new coverage reflects an evaluation of TaskUs\'s potential to generate...

Read More